Form 4: Amgen VP Sells 1,000 Shares Under 10b5-1 Plan

Amgen's VP of Finance and Chief Accounting Officer, Matthew C. Busch, reported the sale of 1,000 shares of common stock.

Summary

• Matthew C. Busch, VP, Finance & CAO of Amgen Inc. (AMGN), sold 1,000 shares of the company's common stock.
• The transaction occurred on February 19, 2026, at a price of $375.79 per share.
• Following this sale, Matthew C. Busch beneficially owns 3,423 shares of Amgen common stock.
• The transaction was executed pursuant to a Rule 10b5-1(c) trading plan, indicating a pre-arranged sale.
• The remaining beneficially owned shares include 60 Dividend Equivalents (DEs) granted under the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan, which are tied to unvested Restricted Stock Units (RSUs) and paid out in shares upon vesting.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal due to the insider sale, although the presence of a 10b5-1 plan mitigates some of the immediate negative implications by indicating a pre-scheduled transaction rather than an opportunistic one.

Negatives

• A high-ranking insider, the VP of Finance and Chief Accounting Officer, sold 1,000 shares of company common stock.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even those conducted under a Rule 10b5-1 plan, are routinely monitored by investors for potential signals regarding management's perception of future stock performance, particularly in the biotechnology and pharmaceutical sector where stock performance can be highly sensitive to pipeline developments and regulatory approvals.

Stakeholder Impact

• Shareholders may interpret the insider sale as a signal regarding the company's future prospects, potentially influencing their investment decisions.

Key Dates

Recommendation

While the insider sale by a key finance executive could be seen as a negative signal, the transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not necessarily indicative of a change in the executive's immediate outlook on the company. Given this context, a 'hold' recommendation is appropriate, advising investors to monitor future insider activity and broader company performance rather than reacting solely to this single planned sale.

Keywords

Amgen, AMGN, Insider Trading, Form 4, Stock Sale, Matthew C. Busch, VP Finance, CAO, Equity Incentive Plan, Rule 10b5-1